Palatine Higher Regional Court

EQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

Retrieved on: 
Tuesday, December 26, 2023
Survival, Research and development, BioNTech, CureVac, Workforce, Operating cost, GSK, Epitope, Webcast, Safety, Business development, RNA, CVAC, Conference, Sąd rejonowy, Astrocytoma, Neoplasm, Pfizer–BioNTech COVID-19 vaccine, Development, Vaccine, Commercial, LNP, Phase II, Acquisition, Immortalised cell line, Animal, GMP, Interim, Palatine Higher Regional Court, Patent, SARS-CoV-2, Tumor microenvironment, Toxicity, Glioblastoma, Antigen, Therapy, Research, Messenger, Mouse, COVID-19, Infection, Clinical trial, District court, Cancer, Patient, CMO, CD8

ET / 3 p.m. CET

Key Points: 
  • ET / 3 p.m. CET
    TÜBINGEN, Germany/BOSTON, USA – November 14, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the third quarter and first nine months of 2023 and provided a business update.
  • Positive preliminary data reported in early 2023 in COVID-19 and flu provided strong validation of CureVac’s mRNA technology platform.
  • All jointly tested candidates are based on CureVac’s proprietary second-generation mRNA backbone, targeting improved intracellular mRNA translation for early and strong immune responses.
  • The first nine months of 2022 were positively impacted by €36.8 million related to the reversal of an outstanding CRO provision.

EQS-News: CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany

Retrieved on: 
Thursday, September 28, 2023
BioNTech, Intellectual property, Palatine Higher Regional Court, Federal Patent Court (Germany), CureVac, Pfizer–BioNTech COVID-19 vaccine, Bird & Bird, Patent, Bird, Sąd rejonowy, CVAC, Generic drug, 3D printing

A ruling on infringement will be provided latest once the validity of the intellectual property rights has been determined by the relevant patent offices.

Key Points: 
  • A ruling on infringement will be provided latest once the validity of the intellectual property rights has been determined by the relevant patent offices.
  • The validity of these intellectual property rights has been challenged by BioNTech.
  • “We are confident in the strength of our intellectual property portfolio and today’s decision indicates that the intellectual property rights at issue are infringed.”
    CureVac filed a patent infringement lawsuit in Germany against BioNTech in early June 2022.
  • Three additional intellectual property rights, added to the infringement lawsuit in July 2023, were not covered in the oral hearing.

10x Wins Injunction From Unified Patent Court Banning Sales of NanoString's CosMx Products in Europe

Retrieved on: 
Tuesday, September 19, 2023
Patent, NanoString Technologies, Genomics, Federal Patent Court (Germany), 10x Genomics, SMI, UPC, Palatine Higher Regional Court, Research, RNA, Science, Invention, Rosenbergia xenium, District court, Investment, Patient, European, Unified Patent Court, European Patent Convention, Court, Health, Douglas v. U.S. District Court ex rel Talk America, Disease, Alex Cartana, Microscope

PLEASANTON, Calif., Sept. 19, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the European Unified Patent Court ("UPC") issued a preliminary injunction against NanoString Technologies, Inc. (Nasdaq: NSTG) for infringing European Patent 4 108 782 B1 ("the EP 782 patent," docket No 459746/2023). The preliminary injunction, issued by a panel of four judges with both legal and technical expertise, prevents NanoString from selling or providing services using its CosMx Spatial Molecular Imager (SMI) instruments and CosMx reagents for RNA detection in all 17 countries of the UPC.

Key Points: 
  • "A patent holder must meet a very high standard to win a preliminary injunction," added Whitaker.
  • "Two separate courts have now found that NanoString's CosMx products infringe two different 10x patents, and three separate courts have preliminarily found the 10x patents valid in the asserted scope.
  • The full opinions of the Unified Patent Court will be posted here when available: 10xgen.com/munich-spatial-news .
  • 10x also intends to seek an injunction against sales of GeoMx as well as ongoing damages.

EQS-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

Retrieved on: 
Tuesday, August 22, 2023
Vaccine, BioNTech, GMP, Operating cost, GSK, Intellectual property, Workforce, Omicron, Palatine Higher Regional Court, Vaccination, COVID-19, Infection, Clinical trial, CureVac, Cancer, Pfizer–BioNTech COVID-19 vaccine, CMO, Part, Astrocytoma, Messenger, Sale, Research and development, Development, Radiation, HIV disease progression rates, Patent, Patient, Hearing, Sąd rejonowy, Epitope, Research, CVAC, Safety, Virus, Pfizer, Cryptocurrency, Fine chemical, Pharmaceutical industry, Glioblastoma

“During the first six months of 2023, we continued building on the momentum from the strong start to the year.

Key Points: 
  • “During the first six months of 2023, we continued building on the momentum from the strong start to the year.
  • “Our unwavering commitment to innovation has enabled us to further expand our intellectual property portfolio, strengthening our mRNA technology ownership.
  • All jointly tested candidates are based on CureVac’s proprietary second-generation mRNA backbone, targeting improved intracellular mRNA translation for early and strong immune responses.
  • The first six months of 2022 were positively impacted by €21.3 million related to the reversal of an outstanding CRO provision.

EQS-News: CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights

Retrieved on: 
Thursday, July 13, 2023
Vaccine, BioNTech, Patent, Intellectual property, Omicron, Palatine Higher Regional Court, Federal Patent Court (Germany), COVID-19, CureVac, Pfizer–BioNTech COVID-19 vaccine, Messenger, Bird & Bird, Bird, Sąd rejonowy, CVAC

Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rights

Key Points: 
  • Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rights
    Three new intellectual property rights added to infringement lawsuit against Pfizer/BioNTech in Germany, increasing number of asserted intellectual property rights to eight
    Tenth patent added to CureVac’s counterclaim against Pfizer/BioNTech in the U.S., covering innovations in mRNA purification methods highly relevant to the manufacturing of Comirnaty®
    TÜBINGEN, Germany – July 13, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that it has strengthened its position in the ongoing patent litigations with Pfizer/BioNTech in Germany and the U.S. by expanding the scope of both cases by asserting new intellectual property rights.
  • Patent litigation in Germany, originally filed by CureVac regarding four of its intellectual property rights in June 2022, was strengthened by the addition of a fifth intellectual property right as announced in May 2023 .These five intellectual property rights have now been extended by three more recent intellectual property rights: DE202021004123U1 and DE202021004130U1, providing protection to COVID-19 variant adapted vaccines, including the Omicron and XBB1.5 variants and EP4023755, relating to split poly A tail mRNA vaccines.
  • A preliminary opinion issued in April 2023 by the German Federal Patent Court supports the validity of the CureVac patent.
  • In the U.S., Pfizer/BioNTech filed its case in late July 2022, asking for confirmation that Comirnaty® does not infringe three CureVac patents.

Seoul Semiconductor Obtains Permanent Injunction Against Various LED Products for Patent Infringement in Europe

Retrieved on: 
Thursday, May 18, 2023
Automotive Manufacturing, Consumer Electronics, Technology, Manufacturing, Professional Services, Patent Law, Environmental, Social and Governance (ESG), Other Technology, Other Manufacturing, Legal, Hardware, Intellectual property, Light-emitting diode, Semiconductor, Oberlandesgericht, Culture, German, Osram, Palatine Higher Regional Court, Multimedia, Unitary patent, LED, KOSDAQ, Patent, Unified Patent Court, Supreme court, Seoul Semiconductor, ESG, Generic drug

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced on May 16 that the Higher Regional Court in Düsseldorf, Germany, issued a final judgement confirming a permanent injunction for infringement of Seoul’s patent against multiple LED companies' LEDs.

Key Points: 
  • Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced on May 16 that the Higher Regional Court in Düsseldorf, Germany, issued a final judgement confirming a permanent injunction for infringement of Seoul’s patent against multiple LED companies' LEDs.
  • View the full release here: https://www.businesswire.com/news/home/20230518005058/en/
    Seoul Semiconductor's patent technology applied to various solutions (Graphic: Seoul Semiconductor Co., Ltd.)
    The permanent injunction judgement extends to LED products from Everlight Electronics Co., Ltd., which were distributed globally through Mouser Electronics Inc., as well as LED products from LED Engin merged into Osram GmbH.
  • Under this new system, patent infringement judgements from the Unified Patent Court will simultaneously take effect in 17 European countries, including Germany, France, and Italy.
  • As a result, Seoul and its affiliates have obtained 14 permanent injunction judgements against manufacturers and distributors of infringing products in the U.S. and Europe over the past five years.

NanoString Responds to Decision of the Regional Court of Munich

Retrieved on: 
Wednesday, May 17, 2023
Professional Services, Health, Legal, Genetics, Research, Science, Biotechnology, Palatine Higher Regional Court, NanoString Technologies, Genomics, Federal Patent Court (Germany), SMI, Harvard College, RNA, Harvard University, Protein, Patent, Fellows, Sąd rejonowy, Federal Patent Court, Synovial joint

The Munich court granted 10x Genomics, Inc. and President and Fellows of Harvard College the right to enforce an injunction against use of the CosMx SMI instrument for RNA detection in Germany.

Key Points: 
  • The Munich court granted 10x Genomics, Inc. and President and Fellows of Harvard College the right to enforce an injunction against use of the CosMx SMI instrument for RNA detection in Germany.
  • NanoString believes the Munich court came to an erroneous conclusion and will appeal the decision.
  • In addition, the decision does not apply to the use of the CosMx SMI instrument for detection of proteins, which NanoString will continue to offer and support.
  • “We respectfully disagree with the recent decision of the Regional Court of Munich,” said Brad Gray, President and CEO of NanoString.

Hytera Prevails Over Patent Lawsuit Filed by Motorola Solutions

Retrieved on: 
Friday, May 5, 2023
Carriers and Services, Technology, Professional Services, Courts, Patent Law, Telecommunications, Software, Audio, Video, Public Policy, Government, Mobile, Wireless, Hardware, Palatine Higher Regional Court, Communication, Blau Mobilfunk, United States Court of Appeals for the Federal Circuit, Complaint, Patent, Motorola Solutions, MSI, HMF, Sąd rejonowy, Radio, SZSE, Generic drug, Hytera

Hytera Communications (SZSE: 002583), a leading global provider of professional communication technologies and solutions, today announced that the Court of Appeals Düsseldorf has ruled in favor of Hytera Communications Corporation Limited (Hytera) and its subsidiary HMF Smart Solutions GmbH (HMF) in patent infringement proceedings initiated by Motorola Solutions Inc. (MSI) at the Regional Court Düsseldorf back in 2017 and 2018.

Key Points: 
  • Hytera Communications (SZSE: 002583), a leading global provider of professional communication technologies and solutions, today announced that the Court of Appeals Düsseldorf has ruled in favor of Hytera Communications Corporation Limited (Hytera) and its subsidiary HMF Smart Solutions GmbH (HMF) in patent infringement proceedings initiated by Motorola Solutions Inc. (MSI) at the Regional Court Düsseldorf back in 2017 and 2018.
  • In 2017, MSI filed a complaint alleging infringement of its European patent EP 2 342 851 B1 by Hytera’s Pseudo-Trunking/TDMA direct mode/TX-none radio functionality.
  • The complaint was initially filed against HMF (“Hytera Mobilfunk GmbH” back then).
  • After Hytera joined as an intervener in these proceedings on the side of HMF, MSI extended its complaint against Hytera, resulting in two parallel proceedings.

EQS-News: Ekosem-Agrar AG: Resolutions of the noteholders' meetings are executed – changes to the bond conditions thus effective

Retrieved on: 
Thursday, December 1, 2022
EBITDA, Milk, Palatine Higher Regional Court, ISIN, Exercise, EUR, James, Hoyer, Newcomer & Smiljanich, P.A., AG, Cattle, ESA, News, Security (finance)

Based on our experience, the conversion of the information on the stock exchange and bank pages will take a few days.

Key Points: 
  • Based on our experience, the conversion of the information on the stock exchange and bank pages will take a few days.
  • The amendments to the bond terms and conditions had been approved by the bondholders with a large majority.
  • The changes to the conditions essentially include the reduction of the interest rates to 2.5% p.a.
  • The resolutions of the noteholders' meetings, which had already been passed in May, could only be executed now, as a bondholder had filed an action for annulment.

DGAP-News: Ekosem-Agrar AG publishes preliminary figures for the first half of 2022

Retrieved on: 
Monday, September 5, 2022
DGAP, Milk, CEO, EBITDA, AG, News, Depreciation, EUR, CO2, ESA, Palatine Higher Regional Court, Cattle, Farm, Wind, Security (finance), Bookkeeping, Film, Agriculture

At 62% (EUR 214 million), raw milk production once again achieved the highest share of total revenue (previous year: 68% or EUR 161 million).

Key Points: 
  • At 62% (EUR 214 million), raw milk production once again achieved the highest share of total revenue (previous year: 68% or EUR 161 million).
  • The milk processing sector was able to grow disproportionately by 77% compared to the previous year (previous year: EUR 35 million) with sales revenues of EUR 62 million.
  • Earnings before interest, tax, depreciation and amortization (EBITDA) increased by 26% to EUR 159 million (previous year: EUR 126 million).
  • Ekosem-Agrar AG, Walldorf, is the German holding company of the Ekoniva Group, one of Russias largest agricultural companies.